@DamianFierce: A new study says low-income patients are less likely to join cancer trials, raising questions of access and education. More | Follow @DamianFierce
> CMO Tecomet is paying $45.2 million for devicemaker Teleflex's orthopedics unit, a business that pulled in about $36 million last year. News
> Paraxel has signed on with the Korea Drug Development Fund, an outfit worth about $1 billion, to help researchers in that country develop and commercialize new treatments. More
> Battelle has secured a 10-year research contract worth up to $102.5 million from the National Institutes of Health, tasked with carrying out clinical tests of vaccines and biologics designed to halt infectious disease. Article
> Clinipace is working with Prometheus Laboratories to run trials of Proleukin, the company's candidate melanoma treatment. Item
> PPD continues its managerial shake-up, appointing former Roche exec Louis Renzetti as vice president of strategic laboratory operations. Release